You have 9 free searches left this month | for more free features.

rituximab

Showing 26 - 50 of 2,665

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Waldenstrom Macroglobulinemia Trial (Venetoclax; Rituximab, DRC)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • Venetoclax; Rituximab
  • DRC
  • (no location specified)
Nov 4, 2022

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Idiopathic Membranous Nephropathy Trial in Beijing (Rituximab, Modified Ponticelli regimen)

Recruiting
  • Idiopathic Membranous Nephropathy
  • Rituximab
  • Modified Ponticelli regimen
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 23, 2023

Waldenström's Macroglobulinemia Trial (zanubrutinib,bendamustine,rituximab)

Not yet recruiting
  • Waldenström's Macroglobulinemia
  • (no location specified)
Aug 4, 2023

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome Trial in Paris (single infusion of Rituximab, single

Not yet recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Steroid-Sensitive Nephrotic Syndrome
  • single infusion of Rituximab
  • single infusion of Obinutuzumab
  • Paris, France
    Robert Debre Hospital
Mar 14, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

Active, not recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • fractionated first dose rituximab
  • Geneva, Switzerland
    University Hospital Geneva
Apr 21, 2023

Nefopam Trial (Nefopam ampule, diphenhydramine ampule)

Not yet recruiting
  • Nefopam
  • Nefopam ampule
  • diphenhydramine ampule
  • (no location specified)
Dec 13, 2022

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Chronic GVHD Trial in Atlanta (Belumosudil, Rituximab)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • Atlanta, Georgia
    Northside Hospital
Sep 21, 2023

Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Nov 22, 2022

Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Oct 31, 2022

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)

Active, not recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Rituximab
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Trial in Rozzano (Rituximab)

Active, not recruiting
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
  • Rituximab
  • Rozzano, Milano, Italy
    Istituto Clinico Humanitas
May 17, 2023

Membranous Nephropathy - PLA2R Induced Trial in Saint Petersburg (Rituximab, Cyclophosphamide, and Corticosteroids)

Recruiting
  • Membranous Nephropathy - PLA2R Induced
  • Rituximab, Cyclophosphamide, and Corticosteroids
  • Saint Petersburg, Russian Federation
    St. Petersburg State Pavlov Medical University
Jan 7, 2023

Glomerulonephritis, Membranous, Nephrotic Syndrome,Idiopathic Trial in Japan (Rituximab (genetical recombination), Placebo)

Not yet recruiting
  • Glomerulonephritis, Membranous
  • Nephrotic Syndrome,Idiopathic
  • Rituximab (genetical recombination)
  • Placebo
  • Anjo, Aichi, Japan
  • +7 more
Jun 13, 2023

Pemphigus, Dermatologic Disease Trial (RiTUXimab Injection)

Not yet recruiting
  • Pemphigus
  • Dermatologic Disease
  • RiTUXimab Injection
  • (no location specified)
Jun 7, 2023

Rheumatic Heart Disease in Children Trial (Rituximab added to standard of care treatment, standard of care treatment)

Not yet recruiting
  • Rheumatic Heart Disease in Children
  • Rituximab added to standard of care treatment
  • standard of care treatment
  • (no location specified)
Jan 3, 2023